Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OS2966 in recurrent high-grade glioma
NCT04608812Phase 1Terminated
- Sponsor
- OncoSynergy
- Start
- Mar 2021
- Primary completion
- Feb 2023
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of OS2966 in glioma, sponsored by OncoSynergy. Primary endpoints: Number of qualifying treatment emergent adverse events or dose limiting toxicities at 28 days and Optimal Biological Dose at 12 months. Started Mar 2021; status: terminated.
02
Drugs
OS2966
03
Conditions
glioma
Beyond the preview
Go deeper on NCT04608812.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04608812.